FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO-86 | CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies prophylaxis Alessia Bellotti,1 Davide Chiasserini,2 Alfredo Megaro,2 Daniela Fruttini,3 Pierluigi Navarra,4 Giuseppe Tringali,4 Paolo Calabresi,5 Lucilla Parnetti,1 Paola Sarchielli1 | 1Department of Medicine and Surgery, Section of Neurology, University of Perugia, Perugia, Italy; 2Department of Medicine and Surgery, Section of Physiology and Biochemistry, University of Perugia, Perugia, Italy; 3Department of Medicine and Surgery, Section of Internal Medicine, University of Perugia, Perugia, Italy; 4Department of Healthcare Surveillance and Bioethics, Section of Pharmacology, Catholic University Medical School, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy; 5Department of Medicine and Surgery, Section of Neurology, Catholic University Medical School, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy
5 -
OC-17 | Profiling miR-30a expression in patients with episodic and chronic migraine Elisa Rubino,1,2 Elisa Maria Piella,1 Giulia Cicilese,1,3 Silvia Boschi,1 Alberto Mario Chiarandon,1 Elena Tamagno,1,3 Michela Guglielmotto,1,3 Innocenzo Rainero1,2 | 1Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Turin, Italy; 2Headache Center, Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino; 3Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano (TO), Italy
1 -
PO-88 | Can tamoxifen and metformin nullify efficacy of CGRP-mAbs migraine prophylaxis? Patrizia Rossi,1,2 Valentina Cima,2 Alessandro Burlina2 | 1Headache Center, 2Neurology Department, San Bassiano Hospital, Bassano del Grappa (VI), Italy
5 -
OC-13 | Monoclonal antibodies targeting CGRP differently affect sleep and psychiatric comorbidities in reproductive and postmenopausal chronic migraine women Giulia Procopio, Letizia Curto, Antonia Di Chirico, Leonardo Troilo, Gabriele Siciliano, Filippo Baldacci, Sara Gori | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy
3 -
PO-70 | A nomogram for the prediction of response to anti-CGRP mAbs: the CGRP score Marina Romozzi,1 Ammar Lokhandwala,2 Catello Vollono,1 David García-Azorín,3 Giulia Vigani,4 Francesco De Cesaris,4 Claudia Altamura,5 Fabrizio Vernieri,5 Paolo Calabresi,1 Sonia Di Tella,6 Luigi Francesco Iannone7 1Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 2Drexel University, Philadelphia, PA, USA; 3Hospital Universitario del Río Hortega, Valladolid, Headache Unit, Department of Neurology, Valladolid, Spain; 4Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy; 5 Neurologia, Dipartimento di Medicina e Chirurgia, Università Campus Bio-Medico di Roma, Rome, Italy; 6Dipartimento di Psicologia, Università Cattolica del Sacro Cuore, Milan, Italy; 7Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
0 -
PO-91 | Real-world evidence of CGRP dual blockade: clinical and biomarker insights from combined therapy in chronic migraine Laura Marino,1 Marta Lioi1, Rosario Iannacchero,2 Michele Trimboli2 | 1Department of Neurology, Magna Graecia University, Catanzaro; 2Institute of Neurology, AOU Renato Dulbecco, Catanzaro, Italy
4 -
PO-22 | Impact of sleep disorders on anti-CGRP monoclonal antibodies treatment response in migraine: a cross-sectional study Costanza Sottani,1 Valerio Brunetti,1,2 Fabiana Cerulli,1 Claudia Garattini,4 Gianluca Avino,5 Paolo Calabresi,1,3 Catello Vollono1,4 | 1Università Cattolica del Sacro Cuore, Dipartimento di Neuroscienze, Rome; 2Stroke Unit, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 3UOC Neurologia, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 4UOC Neurofisiopatologia, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 5Unità di Neurologia, Ospedale Santo Stefano, Prato, Italy
1 -
PO-52 | Long-term efficacy of CGRP mAbs: new insights and current evidence Oreste Marsico,1 Marta Lioi,2 Rosario Iannacchero,3 Michele Trimboli3 | 1Department of Neuroscience, “Giovanni Paolo II” Hospital, Lamezia Terme, Catanzaro, Italy; 2Department of Neurology, Magna Graecia University, Catanzaro, Italy; 3Institute of Neurology, AOU Renato Dulbecco, Catanzaro, Italy
0 -
PO-77 | Real-world evidence of Atogepant efficacy in patients unresponsive to anti-CGRP monoclonals Matteo Cortinovis, Marco Bolchini, Paola Zavarise, Giulia Campana, Giorgio Dalla Volta | Headache Center, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia, Italy
0 -
PO-78 | No changes in blood pressure assessed with the 24-hour Holter monitoring in patients treated with anti-CGRP monoclonal antibodies: a prospective observational study (SAFHYPER) Flavia Lo Castro,1 Niccolò Bonini,2 Luigi Francesco Iannone,1,3 Alberto Boccalini,1 Daria Brovia,1 Luca Pani,1,3 Giuseppe Boriani,2,3 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Cardiology Division, AOU Policlinico di Modena, Modena, Italy; 3Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy
0 -
OC-09 | Atogepant in treatment-refractory chronic migraine: is a revision of current criteria for refractory migraine appropriate? Lorenzo Tartaglione, Marcello Silvestro, Ilaria Orologio, Marcella Marziani, Francesco Maurizio Chianese, Pasquale Sozio, Alessandro Tessitore, Gioacchino Tedeschi, Antonio Russo | Headache Center, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy
6 -
PO-43 | Eptinezumab in migraine patients unresponsive to prior subcutaneous CGRP(-R) monoclonal antibody treatment: a retrospective case series Elena Cresta, Irene Mattioli, Michele Di Pasquale, Alice Lanfranchi, Renata Rao, Alessandro Padovani | Neurology Unit and Headache Centre, Dipartimento di continuità di cura e fragilità, ASST Spedali Civili e Università degli studi di Brescia, Brescia, Italy
0 -
OC-16 | Network-level brain connectivity alterations in an animal model of migraine and the effects of olcegepant treatment Rosaria Greco,1 Gloria Castellazzi,1 Miriam Francavilla,1,2 Chiara Demartini,1 Sara Facchetti,1,2 Daniele Martinelli,1 Cristina Tassorelli1,2 | 1Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia; 2Department of Brain and Behavioral Sciences, University of Pavia, Italy
4 -
PO-19 | Unraveling the spectrum of migraine resistant to treatments: searching for novel biological PHEnotypes and theRApeutic approaches (SPHERA project) M. Giraudo,1,2 R. De Icco,1,2 G. Vaghi,1,2 V. Grillo,1,2 F. Bighiani,1,2 M. Corrado,2 A. Antoniazzi,1,2 F. Cammarota,1,2 B. Agostini,1,2 A. Solfrizzi,1,2 M. Allena,2 E. Guaschino,2 N. Ghiotto,2 R. Greco,2 C. Demartini,2 A. Zanaboni,1,2 M. Francavilla,1,2 S. Facchetti,1,2 G. Sances,2 C. Tassorelli1,2 | 1Department of Brain and Behavioral Sciences, University of Pavia; 2Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy
6 -
PO-39 | Leeds Dependence Questionnaire (LDQ) in migraine: diagnostic utility without predictive value for anti-CGRP (R) response Antonio Munafò,1 Andrea Burgalassi,1 Giulia Vigani,2 Francesco De Cesaris,1 Alberto Chiarugi1,2 | 1Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy; 2Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy
0 -
PO-51 | Rimegepant combined with valproic acid and botulinum toxin in refractory hemiplegic migraine: a case report Gianni Difonzo, Cinzia Tamborino, Adriana Fallacara, Damiano Paolicelli, Maria Pia Prudenzano | Headache Center, “L. Amaducci” Neurological Clinic, Policlinico General Hospital, Bari, Italy
0 -
PO-21 | Evaluating the impact of anti-CGRP monoclonal antibodies on retinal features in migraine patients: a retrospective optical coherence tomography study Chiara Serafini,1 Massimo Cesareo,2 Alessio Martucci,2 Marco Lombardo,2 Vittoria Carla D’Agostino,1 Alessandro Stefani,3 Carlo Nucci,2 Nicola Biagio Mercuri,1,3 Maria Albanese1,3 | 1Regional Referral Headache Center, Neurology Unit, Tor Vergata University Hospital, Rome, Italy 2Ophthalmology Unit, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome; 3Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy
5 -
PO-41 | Eptinezumab for difficult-to-treat migraine: who responds and who needs more Alessandro Visentini,1,2,3 Roberta Messina,1,2,3 Ilaria Cetta,1,2,3 Edorardo Ratto,1 Laura Zanandrea,1,3 Federica Genovese,1,2,3 Irene Chinali,1 Bruno Colombo,1 Massimo Filippi1,2,3 | 1Neurology Unit and 2Neuroimaging Research Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; 3Vita-Salute San Raffaele University, Milan, Italy
0 -
PO-87 | Dual inhibition of FAAH and TRPV1 receptors counteracts nitroglycerin-induced migraine-like symptoms only in male rats Miriam Francavilla,1,2 Sara Facchetti,1,2 Chiara Demartini,1 Anna Maria Zanaboni,1,2 Michela Palmisani,3 Valentina Franco,3 Rosaria Greco,1 Cristina Tassorelli1,2 | 1Section of Translational Neurovascular Research, IRCCS Mondino Foundation, Pavia; 2Department of Brain and Behavioral Sciences, University of Pavia; 3Department of Internal Medicine and Therapeutics, Clinical and Experimental Pharmacology Unit, University of Pavia, Italy
6 -
PO-69 | Three-month atogepant treatment modulates dopaminergic-related functional connectivity in episodic migraine Davide Fedeli,1 Danilo Antonio Montisano,1 Greta Demichelis,1 Giuseppe Ciullo,1,2 Jean Paul Medina Carrion,1 Maria Grazia Bruzzone,1 Emilio Ciusani,1 Alessandra Erbetta,1 Marina Grisoli,1 Erika Guastafierro,1 Domenico D’Amico,1 Alberto Raggi,1 Anna Nigri,1 Licia Grazzi1 | 1Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 2University of Parma, Parma, Italy
0 -
PO-84 | Inhibiting the peripheral degradation of anandamide reduces trigeminal hyperalgesia in a model of dural neurogenic inflammation via a CB1/CB2-independent mechanism Chiara Demartini,1 Rosaria Greco,1 Miriam Francavilla,1,2 Sara Facchetti,1,2 Cristina Tassorelli1,2 | 1Section of Translational Neurovascular Research, IRCCS Mondino Foundation, Pavia, Italy; 2Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
5 -
PO-57 | Early treatment with atogepant improves sleep quality without sleep-related adverse events: a prospective observational study Alberto Boccalini,1 Luigi Francesco Iannone,1,2* Flavia Lo Castro,1 Daria Brovia,1 Marina Romozzi,3,4 Fabrizio Vernieri,5,6 Claudia Altamura,5,6 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
0 -
OC-05 | Mid-term effectiveness and tolerability of atogepant in the prevention of migraine: a real life, prospective, multicentric study (the STAR study) Fabrizio Vernieri,1 Luigi Francesco Iannone,2,3 Gabriele Sebastianelli,4 Flavia Lo Castro,2, Federico De Santis,5 Michele Corrado,6 Marilena Marcosano,1 Raffaele Ornello,5 Licia Grazzi,7 Danilo Antonio Montisano,7 Francesco De Cesaris,8 Antonio Munafò,8 Gianluca Avino,9 Michele Trimboli,10 Maria Albanese,11 Antonio Russo,12 Giorgio Dalla Volta,13 Marina Romozzi,14 Paola Merlo,15 Maria Pia Prudenzano,16 Maria Rosaria Valente,17 Innocenzo Rainero,18 Giada Giuliani,19 Luisa Fofi,1 Alberto Doretti,20 Gloria Vaghi,6 Francesca Pistoia,5 Delfina Ferrandi,21 Stefania Battistini,22 Simona Sacco,5 Simona Guerzoni,2 Claudia Altamura1 on behalf of the Italian Headache Registry (RICe) Study Group | 1Fondazione Policlinico Campus Bio-Medico, Roma; 2AOU Policlinico di Modena; 3Università di Modena e Reggio Emilia. 4Sapienza University of Rome Polo Pontino, Latina; 5University of L’Aquila; 6University of Pavia, Pavia, Italy and IRCCS Mondino Foundation, Pavia; 7IRCCS Istituto Neurologico Carlo Besta, Milano; 8AOU Careggi, Firenze; 9SOC Neurologia, Ospedale di Prato, Prato; 10Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 11Università Roma Tor Vergata, Roma; 12Università della Campania "Luigi Vanvitelli", Napoli; 13U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia; 14Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma; 15UO di Neurologia, Humanitas Gavazzeni, Bergamo; 16Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Consorziale di Bari; 17Dipartimento di Neuroscienze, Azienda Sanitaria Universitaria Integrata di Udine; 18Dipartimento di Neuroscienze, Città della Salute e della Scienza di Torino; 19Centro per la diagnosi e terapia delle cefalee, Policlinico Umberto I, Roma; 20IRCCS Istituto Auxologico Italiano, Milano; 21AOU Alessandria; 22University of Siena, Siena, Italy
2 -
PO-13 | HD-EEG Delta connectivity rapidly alters after one month of atogepant in migraine patients Maria Albanese,1,2 Matteo Conti,1 Silvio Bagetta,1 Federico Carparelli,2 Vittoria Carla D’Agostino,2 Fabio Placidi,1,2 Alessandro Stefani,1,2 Nicola Biagio Mercuri,1-3 | 1Department of Systems Medicine, University of Rome Tor Vergata, Rome; 2Neurology Unit, Tor Vergata University Hospital, Rome; 3IRCCS Santa Lucia Foundation, Rome, Italy
8 -
PO-80 | Real-world effectiveness of atogepant for the preventive treatment of migraine in a cohort of multi -refractory patients: a single center study M. De Luca,1 L. Ferraù,1 A. Cafarchio,2 M.S. Adragna,1 M. Autunno1 | 1Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 2Department of Medicine and Health Sciences “Vincenzo Tibero” DIMES, University of Molise, Campobasso, Italy
0 -
OC-14 | Efficacy of eptinezumab during a migraine attack: preliminary data from an Italian multicenter real-world experience (the BEFREE study) Luisa Fofi,1 Claudia Altamura,1 Marilena Marcosano,1 Alberto Doretti,2 Francesca Pistoia,3 Antonio Granato,4 Simona Guerzoni,5 Michele Trimboli,6 Licia Grazzi,7 Danilo Antonio Montisano,7 Gianluca Avino,8 Gabriele Sebastianelli,9 Carla Fasano,10 Elisa Maria Piella,11 Nicoletta Brunelli,1 Luigi Francesco Iannone,5,12 Fabrizio Vernieri1 on behalf of the Italian Headache Registry (RICe) Study Group | 1Neurosonology and Headache Unit, Fondazione Policlinico Campus Bio-Medico, Rome; 2IRCCS Istituto Auxologico Italiano - Department of Neurology and Laboratory of Neuroscience - Milan; 3University of L’Aquila; 4Headache Center, Neurology Clinic, University of Trieste, University Hospital of Trieste; 5AOU Policlinico di Modena; 6Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 7Headache Center, Neuroalgology Dpt, IRCCS Foundation "Carlo Besta" Neurological Institute, Milan; 8SOC Neurologia, Ospedale Santo Stefano, USL Toscana Centro, Prato; 9La Sapienza University of Rome Polo Pontino, Latina; 10Headache and Cerebrovascular Diseases Center, Neurology Unit 2, Careggi University Hospital, Florence; 11Department of Neuroscience “Rita Levi Montalcini”, University of Turin; 12Università di Modena e Reggio Emilia, Italy
3 -
PO-35 | Treatment of chronic and episodic migraine with atogepant improves quality of life in patients with comorbid multiple sclerosis: the experience of the Headache Center at Spaziani Hospital, Frosinone Laura Borrello; Fabiana Marinelli; Maria Lorena Marziale; Ilaria Avallone; Fulvio Ferrante; Roberto De Simone | Neurology Unit, Headache Center, Multiple Sclerosis Center, UOC Pharmacy, Spaziani Hospital, Frosinone (FR), Italy
0 -
PO-62 | Preventive migraine treatment in patients under 25: a 24-month observational study on adherence, therapeutic switching, and prescription determinant factors Marilena Marcosano,1 Nicoletta Brunelli,1 Luisa Fofi,1 Laura Papetti,2 Fabiana Ursitti,2 Massimiliano Valeriani,2 Fabrizio Vernieri,1 Claudia Altamura1 | 1Headache and Neurosonology Unit, Fondazione Policlinico Campus Biomedico di Rome, Rome, Italy; 2Developmental Neurology, Bambino Gesù Children Hospital, IRCCS, Rome, Italy
0 -
PO-44 | Effectiveness of fremanezumab as preventive treatment of migraine up to 24 months: response rates from the Italian analysis of the PEARL study Alberto Doretti,1 Anna Ambrosini,2 Simone Braca,3 Florindo D’Onofrio,4 Elisa Maria Piella,5 Pinar Kokturk,6 Rosario Iannacchero7 | 1Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; 2Mediterranean Neurological Institute NEUROMED IRCCS, Pozzilli (IS), Italy; 3Headache Centre, University of Naples “Federico II”, Naples, Italy; 4UOSD Stroke Unit, S.G. Moscati Hospital, Avellino, Italy; 5Neurosciences Department, University of Turin, Turin, Italy; 6Teva Netherlands B.V., Haarlem, The Netherlands; 7Department of Neurology, Headache Center, Regional Hospital “Pugliese-Ciaccio”, Catanzaro, Italy
0 -
PO-82 | Integrated approach with detoxification, CGRP monoclonal antibodies and psychoeducational support in two patients with complex medication overuse headache Claudia Lanni,1 Federica Papini,2 Chiara Prevost,3 Alessandro Canessa,3 Lucia Testa,3 Cristoforo Comi,2 Delfina Ferrandi3 | 1Department of Psychology “Santi Antonio e Biagio”, University Hospital, Alessandria, Italy; 2Neurology Unit, Department of Transitional Medicine, University of Piemonte Orientale, and University Hospital “Maggiore della Carità”, Novara, Italy; 3Neurology Unit, “Santi Antonio e Biagio” University Hospital, Alessandria, Italy
5 -
PO-76 | Atogepant reduces psychological dependence to acute treatments evaluated with the Leeds dependence questionnaire (LDQ): a prospective observational study Luigi Francesco Iannone,1,2 Marina Romozzi,3,4 Alberto Boccalini,1 Flavia Lo Castro,1 Claudia Altamura,5 Fabrizio Vernieri,5 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
0 -
PO-56 | The role of bilateral greater occipital nerve block in resistant chronic migraine with medication overuse Leonardo Troilo, Letizia Curto, Giulia Procopio, Antonia Di Chirico, Gabriele Siciliano, Sara Gori, Filippo Baldacci | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy
0